Cell signaling

Indivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld

Retrieved on: 
Tuesday, July 31, 2018
Chemistry, RTT, Cell signaling, Morphinans, Signal transduction, Drug rehabilitation, Opioid antagonists, Alcohols, Buprenorphine/naloxone, Buprenorphine, Indivior, Naloxone

The PI prohibits DRL from using, importing, selling, or offering to sell its generic buprenorphine/naloxone sublingual film product.

Key Points: 
  • The PI prohibits DRL from using, importing, selling, or offering to sell its generic buprenorphine/naloxone sublingual film product.
  • Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.
  • You should not drink alcohol while taking SUBOXONE Film, as this can lead to loss of consciousness or even death.
  • For more information about SUBOXONE Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablets (CIII), or SUBUTEX (buprenorphine) Sublingual Tablets (CIII), please see the respective full Prescribing Information and Medication Guide at www.suboxoneREMS.com .

Cell Signaling Market Size Global Industry to Grow at a CAGR of 6.8% During the Period 2018-2025

Retrieved on: 
Friday, July 27, 2018
Biology, Cell biology, Cell communication, Cell signaling, Systems biology, Cellular Signalling, Signal transduction

Global Cell Signaling Market Report 2018 statistical surveying furnishes industry outline and examination with 2025 Cell Signaling market gauges and additionally organization profile, item picture and determination with limit creation, value, cost, generation esteem and more for real makers.

Key Points: 
  • Global Cell Signaling Market Report 2018 statistical surveying furnishes industry outline and examination with 2025 Cell Signaling market gauges and additionally organization profile, item picture and determination with limit creation, value, cost, generation esteem and more for real makers.
  • Cell signaling (cell signalling in British English) is part of any communication process that governs basic activities of cells and coordinates all cell actions.
  • The cell signaling consumables segment is estimated to account for the largest share of the cell signaling market in 2017.
  • Some of the tables and figures provided in Global Cell Signaling Market Report 2018 research report include:
    Table North America Cell Signaling Production, Consumption, Import & Export (K MT) (2013-2018)
    Table Europe Cell Signaling Production, Consumption, Import & Export (K MT) (2013-2018)
    Table China Cell Signaling Production, Consumption, Import & Export (K MT) (2013-2018)
    Table Japan Cell Signaling Production, Consumption, Import & Export (K MT) (2013-2018)
    Table Southeast Asia Cell Signaling Production, Consumption, Import & Export (K MT) (2013-2018)
    Table India Cell Signaling Production, Consumption, Import & Export (K MT) (2013-2018)
    Deep Research Reports is digital database of syndicated market reports for global and China industries.

No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist

Retrieved on: 
Monday, July 23, 2018
Biology, Cell biology, Immune system, Cell signaling, Membrane biology, Receptor, Receptors, Immune checkpoint, Immune receptor, NMDA receptor

Regen BioPharma Inc.'s (OTCQB: RGBP) and (OTCQB: RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed no signs of toxicity.

Key Points: 
  • Regen BioPharma Inc.'s (OTCQB: RGBP) and (OTCQB: RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed no signs of toxicity.
  • Regen has methodically optimized small molecules that bind to, and activate, the NR2F6 nuclear receptor.
  • He also adds,"This is very exciting, as it indicates that the drug will likely be safe in animals as we begin efficacy testing."
  • The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.

No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist

Retrieved on: 
Monday, July 23, 2018
Biology, Cell biology, Immune system, Cell signaling, Membrane biology, Receptor, Receptors, Immune checkpoint, Immune receptor, NMDA receptor

Regen BioPharma Inc.'s (OTCQB: RGBP) and (OTCQB: RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed no signs of toxicity.

Key Points: 
  • Regen BioPharma Inc.'s (OTCQB: RGBP) and (OTCQB: RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed no signs of toxicity.
  • Regen has methodically optimized small molecules that bind to, and activate, the NR2F6 nuclear receptor.
  • He also adds,"This is very exciting, as it indicates that the drug will likely be safe in animals as we begin efficacy testing."
  • The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.

Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder

Retrieved on: 
Monday, July 16, 2018
Chemistry, Cell signaling, Morphinans, RTT, Neurochemistry, Drug rehabilitation, Opioid antagonists, Alcohols, Buprenorphine, Opioid use disorder, Camurus, Naloxone

"We are pleased that the FDA has assigned a target action date for a US approval decision for CAM2038 in Q4 2018," said Fredrik Tiberg, President and CEO of Camurus.

Key Points: 
  • "We are pleased that the FDA has assigned a target action date for a US approval decision for CAM2038 in Q4 2018," said Fredrik Tiberg, President and CEO of Camurus.
  • "This is an important step for Camurus and our commitment to providing people living with opioid dependence worldwide with a new, flexible, long-acting treatment option.
  • If approved, CAM2038 would be the first long-acting treatment for OUD available in both weekly and monthly formulations for use through all stages of a patient's treatment journey.
  • Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial.

Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder

Retrieved on: 
Monday, July 16, 2018
Chemistry, Cell signaling, Morphinans, RTT, Neurochemistry, Drug rehabilitation, Opioid antagonists, Alcohols, Buprenorphine, Opioid use disorder, Camurus, Naloxone

"We are pleased that the FDA has assigned a target action date for a US approval decision for CAM2038 in Q4 2018," said Fredrik Tiberg, President and CEO of Camurus.

Key Points: 
  • "We are pleased that the FDA has assigned a target action date for a US approval decision for CAM2038 in Q4 2018," said Fredrik Tiberg, President and CEO of Camurus.
  • "This is an important step for Camurus and our commitment to providing people living with opioid dependence worldwide with a new, flexible, long-acting treatment option.
  • If approved, CAM2038 would be the first long-acting treatment for OUD available in both weekly and monthly formulations for use through all stages of a patient's treatment journey.
  • Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial.

Global Outlook on Cancer Therapies 2018-2030: Transcription Factors, GTPases, Phosphatases and GPCRs

Retrieved on: 
Wednesday, July 4, 2018
Biology, Cell biology, Biochemistry, Signal transduction, Membrane biology, Peripheral membrane proteins, RTT, Cell signaling, G protein–coupled receptor, G protein, GTPase, Breast cancer

The "New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030" report has been added to ResearchAndMarkets.com's offering.
  • It features an elaborate discussion on the future potential of this evolving domain, focusing on phosphatases, transcription factors, small GTPases (specifically Ras family) and undruggable G-protein coupled receptors (GPCRs).
  • Of these, pancreatic cancer (23%) is the most common; other popular indications include breast cancer (21%), lung cancer (19%) and colorectal cancer (16%).
  • The focus of the report is on difficult-to-modulate phosphatases, transcription factors, small GTPases (specifically Ras family) and GPCRs.

Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting

Retrieved on: 
Monday, July 2, 2018
Biology, Cell biology, Cell signaling, Developmental neuroscience, Growth factors, Neurotrophic factors, Peptide hormones, Brain-derived neurotrophic factor, NMDA receptor, Synaptogenesis, Insulin-like growth factor 1, MTOR

This has been demonstrated in pre-clinical models because our target PKC epsilon activates synaptic growth factors like BDNF, NGF and IGF-1.

Key Points: 
  • This has been demonstrated in pre-clinical models because our target PKC epsilon activates synaptic growth factors like BDNF, NGF and IGF-1.
  • The data indicate that PKC's synaptogenesis efficacy cannot occur when the NMDA receptor is blocked.
  • We are excited to be presenting this new data at this prestigious international forum" stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope.
  • Clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share the Company's views of the Phase 2 data.

FDA Approves ARISTADA INITIO™ for the Initiation of ARISTADA® for Schizophrenia

Retrieved on: 
Monday, July 2, 2018
Neurochemistry, Chemistry, Cell signaling, Chloroarenes, Piperazines, Atypical antipsychotics, Antidepressants, Mood stabilizers, Aripiprazole, Ketamine, Palifermin

The first ARISTADA dose may be administered on the same day as ARISTADA INITIO or up to 10 days thereafter.

Key Points: 
  • The first ARISTADA dose may be administered on the same day as ARISTADA INITIO or up to 10 days thereafter.
  • ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, can be used to initiate onto any dose of ARISTADA.
  • The first ARISTADA dose may be administered on the same day as ARISTADA INITIO or up to 10 days thereafter.
  • Injection-Site Reactions: In pharmacokinetic studies evaluating ARISTADA INITIO, the incidences of injection site reactions with ARISTADA INITIO were similar to the incidence observed with ARISTADA.

FDA Approves ARISTADA INITIO™ for the Initiation of ARISTADA® for Schizophrenia

Retrieved on: 
Monday, July 2, 2018
Neurochemistry, Chemistry, Cell signaling, Chloroarenes, Piperazines, Atypical antipsychotics, Antidepressants, Mood stabilizers, Aripiprazole, Ketamine, Palifermin

The first ARISTADA dose may be administered on the same day as ARISTADA INITIO or up to 10 days thereafter.

Key Points: 
  • The first ARISTADA dose may be administered on the same day as ARISTADA INITIO or up to 10 days thereafter.
  • ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, can be used to initiate onto any dose of ARISTADA.
  • The first ARISTADA dose may be administered on the same day as ARISTADA INITIO or up to 10 days thereafter.
  • Injection-Site Reactions: In pharmacokinetic studies evaluating ARISTADA INITIO, the incidences of injection site reactions with ARISTADA INITIO were similar to the incidence observed with ARISTADA.